RANI
Rani Therapeutics Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.65
+1.51%Year over year
Reported trailing growth
- Revenue
- +306.4%
- EBITDA
- +32.2%
- EBIT
- +33.1%
- EPS
- +70.4%
- Free cash flow
- +34.9%
- Operating cash flow
- +34.6%
Forward estimates
Based on analyst estimates
- Revenue
- +231.6%
- EBITDA
- -13.1%
- EPS
- +25.7%
Three-year CAGR
- Revenue
- +58.9%
- EBITDA
- +26.5%
- EBIT
- +28.1%
- Net income
- +1.1%
- EPS
- +57.1%
- Free cash flow
- +47.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026